Key regions: United Kingdom, Germany, France, South Korea, Italy
Burundi, a landlocked country in East Africa, has been facing challenges in accessing COVID-19 vaccines due to various factors.
Customer preferences: The Burundian government has been cautious in its approach to COVID-19 vaccines, with concerns over their safety and efficacy. This has led to a low demand for vaccines among the population, with many opting to rely on traditional medicine instead. Additionally, there is a lack of awareness and education about the benefits of vaccination, further contributing to the low demand.
Trends in the market: The COVID-19 vaccines market in Burundi is still in its early stages, with limited availability of vaccines. The government has received donations of vaccines from various sources, including the COVAX facility, but the number of doses is not sufficient to cover the entire population. As a result, the government has prioritized certain groups, such as healthcare workers and the elderly, for vaccination.
Local special circumstances: Burundi has faced political instability and economic challenges in recent years, which have impacted its healthcare system. The country has a limited healthcare infrastructure and resources, which makes it difficult to distribute and administer vaccines effectively. Additionally, there are logistical challenges in transporting vaccines to remote areas of the country.
Underlying macroeconomic factors: Burundi is one of the poorest countries in the world, with a low GDP per capita and high levels of poverty. This has made it difficult for the government to invest in healthcare infrastructure and resources, which has further hindered its ability to respond to the COVID-19 pandemic. Additionally, the country has faced challenges in accessing financing from international organizations due to concerns over its human rights record and political stability. In conclusion, the COVID-19 vaccines market in Burundi is facing challenges due to low customer demand, limited availability of vaccines, and logistical and economic challenges. The government will need to address these issues in order to effectively distribute and administer vaccines to the population and control the spread of the virus.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
